Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Pancreatic Cancer Approved as Add'l Indication for Tarceva: Chugai
July 18, 2011
- DPC Subcommittee to Look at Fixed-sum Reimbursement per Hospitalization for High-priced Drugs
July 18, 2011
- Further Consolidation of Dispensing Pharmacies Expected: Mr Ubunuki of Yano Research
July 18, 2011
- GSK Obtains Marketing Approval for Rotarix
July 18, 2011
- Taisei Kako Co-develops New Prefilled Syringe with Suzuken
July 18, 2011
- Kyowa Kirin to Enforce Safe Driver Education for New MRs
July 18, 2011
- 3 Products Including 4-Valent HPV Vaccine Gardasil Approved: MSD
July 18, 2011
- Nippon Kayaku Takes over Manufacturing Approval for Gelpart from Astellas
July 18, 2011
- Korosho to Announce Stance on Copayments for OTC-like Drugs by Year-end
July 18, 2011
- Takeda Obtains Approval for Liovel Combination Tab
July 18, 2011
- Korosho Panel Fails to Form Consensus on HbA1c Data Reporting
July 18, 2011
- Onbrez Approved for COPD: Novartis
July 18, 2011
- Hepatitis B Settlements May Require General Tax Increase: Health Minister Hosokawa
July 18, 2011
- Astellas Sells DPP-4 Inhibitor-related Patent Estate to Royalty Pharma for US$609 Mil.
July 11, 2011
- FDA Accepts Pfizer's Application for Axitinib for RCC
July 11, 2011
- Celecoxib Significantly Lowers Incidence of Ulcers vs Loxoprofen
July 11, 2011
- CMIC to Acquire Investigational Drug Manufacturing Facilities from Daiichi Sankyo
July 11, 2011
- Regenerative Medicine Industry Organization Kicks Off
July 11, 2011
- JES Calls for Approval of Monotherapy with Novel Antiepileptic Agents
July 11, 2011
- Sogo Medical to Increase Number of Mentaio Pharmacies to 20 in 3 Years
July 11, 2011
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…